UNC Chapel Hill AAV-NAGLU Gene Therapy Patent
Summary
The University of North Carolina at Chapel Hill has received USPTO Patent US12605465B2 for recombinant nucleic acid compositions encoding α-N-acetylglucosaminidase (NAGLU), with vectors optimized for human cell expression. The 19 claims cover gene therapy vectors and methods for increasing NAGLU secretion and for treatment and prevention of mucopolysaccharidosis IIIB. The patent application US17907025 was filed on March 22, 2021.
“Recombinant nucleic acid comprising nucleotides encoding α-N-acetylglucosaminidase (NAGLU).”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 29 changes logged to date.
What changed
USPTO has granted Patent US12605465B2 to The University of North Carolina at Chapel Hill, covering recombinant nucleic acid compositions encoding α-N-acetylglucosaminidase (NAGLU) and AAV vectors for gene therapy delivery. The patent includes 19 claims directed to vectors comprising NAGLU sequences optimized for expression in human cells, methods of increasing NAGLU secretion from cells, and methods for treatment and prevention of mucopolysaccharidosis IIIB.
Licensees, researchers, and biotech firms developing gene therapies for lysosomal storage disorders should review this patent to assess freedom-to-operate implications for any overlapping MPS IIIB programs. The patent's specific claims around optimized NAGLU expression and secretion methods may affect product development strategies in this therapeutic area.
Archived snapshot
Apr 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB
Grant US12605465B2 Kind: B2 Apr 21, 2026
Assignee
The University of North Carolina at Chapel Hill
Inventors
Haiyan Fu, Tierra Bobo
Abstract
Recombinant nucleic acid comprising nucleotides encoding α-N-acetylglucosaminidase (NAGLU). Vectors comprising the recombinant nucleic acid for delivery to a subject. In an aspect the NAGLU sequences optimized for expression in human cells. Methods of using the vector to increase secretion of NAGLU from a cell and for treatment and prevention of mucopolysaccharidosis IIIB.
CPC Classifications
A61K 48/005 C12N 9/2402 C12N 15/86 C12Y 302/0105
Filing Date
2021-03-22
Application No.
17907025
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.